MPLN buys MiSeqDx, 4/14
April 2014—Molecular Pathology Laboratory Network, of Maryville, Tenn., acquired the Illumina MiSeqDx, a next-generation sequencing system cleared by the FDA for targeted sequencing of human genomic DNA.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Partners: UCSF, Quest, 4/14
April 2014—UC San Francisco and Quest Diagnostics formed a collaboration to accelerate the translation of biomedical research into advanced diagnostics in the field of precision medicine for improved patient care, treatment, and outcomes.
DNA, RNA stabilization reagents
April 2014—In a licensing agreement between Biomatrica and ATCC, Biomatrica will supply DNAstable and RNAstable reagents for the stabilization of DNA and RNA standards.
Licensing agreement for GastroPanel, 4/14
April 2014—Finnish health care company Biohit Oyj and Randox Laboratories signed a licensing agreement giving Randox the worldwide licensing rights for GastroPanel.
Artus C. difficile kit, 4/14
April 2014—IMDx’s artus C. difficile QS-RGQ kit received CE marking for use with QIAsymphony SP/AS and Rotor-Gene Q instruments. Concurrently, in December 2013, a Premarket Notification 510(k) for the test was submitted to the FDA for review.
Troponin I POC test
April 2014—Trinity Biotech’s Meritas Troponin I (TnI) point-of-care test obtained CE marking. The test enables accurate triage and intervention for emergency department patients with possible myocardial infarction; results are available in 15 minutes.
Audit Web site, 4/14
April 2014—Audit MicroControls launched a new Web site, adding online ordering, access to Auditor QC, peer review data retrieval, and search functions by instrument, analyte, or indication. It also offers information about quality control products, calibration verification/linearity products, Audit Ship, and Audit Faxback.
RBCX cleared on Spectra Optia system, 4/14
April 2014—Terumo BCT received FDA 510(k) clearance for red blood cell exchange on the Spectra Optia Apheresis System.
ELISA reagents, 4/14
April 2014—Vector Laboratories’ Avidin-HRP and Streptavidin-HRP are optimized to yield high signal-to-noise ratios in solid phase assays, such as ELISAs and blotting applications.
IHC guidebook, 3/14
March 2014—The sixth edition of The Educational Guidebook: IHC Staining Methods, published by Dako, is now available. The guidebook is used as a teaching and learning tool worldwide and serves as a reference for ensuring correct staining processes within the lab. Several experts within the field of IHC wrote this new edition and Clive R. Taylor, MD, is the editor.